Clinical Trials

    A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)

    Investigator: Kai Sun

    Study Coordinator: Jawairia Jawed

    Status: Open Not Enrolling

    ClinicalTrials.gov Number: NCT04961996

    Phone: 346.356.3603

    Protocol Number: PRO00032959

    Description


    This is a Phase III, global, randomized, open-label, multicenter, study evaluating the efficacy and safety of adjuvant giredestrant compared with endocrine therapy of physician's choice in participants with medium- and high-risk Stage I-III histologically confirmed estrogen receptor (ER)-positive and human epidermal growth factor receptor 2 (HER2)-negative early breast cancer.